BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Orca Bio
• 

  Career Advice

  How to Negotiate Your Salary According to Market Value

  In our comprehensive guide to salary negotiation, we’ll teach you what a market salary is, how to research a market value salary and, ultimately, how to negotiate your salary according to market value.

  October 1, 2024

   · 

  5 min read

   · 

  Franklin Carpenter
• 

  GLP-1

  Obesity Startup Metsera Inks Manufacturing Pact With Amneal on Heels of Phase I Readout

  A week after it released positive early-stage data, Metsera has partnered with Amneal Pharmaceuticals in an effort to secure the development and supply of its investigational weight loss therapy MET-097.

  October 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Schizophrenia

  The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia

  From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite the journey to market. Former Karuna and Lilly executives discuss the “accidental” and “serendipitous” discovery.

  October 1, 2024

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Immunology and inflammation

  Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment

  William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.

  October 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Kailera Launches With $400M to Advance China-Developed Obesity Assets

  Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million Series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.

  October 1, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Legal

  Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition

  District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol Myers Squibb because it is not a properly appointed trustee for shareholders’ contingent value rights.

  October 1, 2024

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  J&J Reverses Course on 340B Rebate Plans Following HRSA Warning

  Faced with potential monetary fines, Johnson & Johnson said Monday it is abandoning a proposed 340B rebate plan for hospitals involving two of its blockbuster drugs, Stelara and Xarelto.

  October 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Shattuck Labs to Lay Off 40% of Workforce

  As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.

  October 1, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• Press Releases

  Florey Biosciences spins out of Harvard Wyss Institute to develop a medical food aimed at managing impacts of antibiotic use

  October 1, 2024

   · 

  1 min read